Immunocan Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech developing next-generation personalized and off-the-shelf cell therapies and cancer vaccines for solid tumors.
Oncology
Technology Platform
Integrated platform for developing next-generation cell therapies (CAR-T, TCR-T) and therapeutic cancer vaccines, with a focus on solid tumors.
Opportunities
If successful, could address the immense unmet need in solid tumor immunotherapy with a differentiated product.
Risk Factors
High technical and clinical development risk associated with pioneering cell therapies for solid tumors, alongside complex manufacturing hurdles.
Competitive Landscape
Enters a highly competitive and capital-intensive field of cell therapy with many players targeting similar solid tumor challenges.